Your browser doesn't support javascript.
loading
Association of KRAS mutation with tumor deposit status and overall survival of colorectal cancer.
Zhang, Meifang; Hu, Wenwei; Hu, Kun; Lin, Yong; Feng, Zhaohui; Yun, Jing-Ping; Gao, Nan; Zhang, Lanjing.
Afiliação
  • Zhang M; Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Hu W; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Hu K; Department of Pathology, Princeton Medical Center, 1 Plainsboro Rd, Plainsboro, NJ, 08536, USA.
  • Lin Y; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Feng Z; Department of Pathology, University at Buffalo, Buffalo, NY, USA.
  • Yun JP; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Gao N; Department of Biostatistics, School of Public Health, Rutgers University, Piscataway, NJ, USA.
  • Zhang L; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Cancer Causes Control ; 31(7): 683-689, 2020 Jul.
Article em En | MEDLINE | ID: mdl-32394229
ABSTRACT

PURPOSE:

To examine associations of KRAS mutation with tumor deposit status and overall survival in colorectal cancer (CRC) patients.

METHODS:

This retrospective cohort study included patients with incidental CRC diagnosed during 2010-2014 and recorded statuses of KRAS and tumor deposit in the National Cancer Database of the USA. Multivariable logistic regression and time-varying Cox regression analyses were used.

RESULTS:

We included 45,761 CRC patients with KRAS status (24,027 [52.5%] men, 24,240 [53.0%] < 65 years old, 17,338 [37.9%] with KRAS mutation). Adjusted for microsatellite instability, age, pathologic stage and tumor grade, KRAS mutation (versus wild type) was associated with tumor deposit presence (odds ratio = 1.11, 95% CI 1.02-1.20). KRAS mutation was also linked to worse overall survival of CRC patients regardless of tumor deposit status (adjusted Hazard ratio [HR] = 1.20, 95% CI 1.07-1.33 for CRC with tumor deposits, and adjusted HR = 1.24, 95% CI 1.14-1.35 or CRC without) or tumor stage (adjusted HR = 1.32, 95% CI 1.14-1.54 for early-stage and adjusted HR = 1.18, 95% CI 1.10-1.27 for late-stage). Microsatellite instability was associated with better overall survival in CRC without tumor deposit (adjusted HR = 0.89, 95% CI 0.79-0.99), but not in CRC with tumor deposit (adjusted HR = 1.12, 95% CI 0.97-1.30).

CONCLUSION:

KRAS mutation is independently associated with tumor deposit presence and a worse overall survival in CRC patients.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Proteínas Proto-Oncogênicas p21(ras) / Mutação Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Proteínas Proto-Oncogênicas p21(ras) / Mutação Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2020 Tipo de documento: Article